Skip to main content
OpenTrials
Completed

NCT Number: NCT06244498

Tranexamic Acid After Pathological Fracture Treated With Modular Arthroplasty

This study assesses the safety and efficacy of TXA for patients treated for pathological femur fractures using modular prosthetics.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Metastases to Bone Neoplasm Metastasis Neoplasms Neoplastic Processes Pathologic Processes Pathological Conditions, Signs and Symptoms

Sex eligibility

All sexes

Study type

Observational

Primary location

SzSPOO Brzozów

Brzozów, Podkarpackie Voivodeship, 36-200, Poland

About this study

Tranexamic acid is an efficacious medication for curtailing blood loss, haemoglobin drop, and the requirement for transfusions. Additionally, it is a secure medication, even when administered to oncology patients receiving reduction haemarthroplasty for pathological femoral fractures.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patological fracture
  • Arthroplasty using a modular prosthesis.

Exclusion criteria

  • threatened fracture
  • intraoperative blood transfusion
  • fracture fixation

Treatment and study plan

Tranexamic acid injection

Drug

Tranexamic acid were administered at a dose of 1.0 g during the induction of anaesthesia and immediately after surgery.

Primary outcomes

  1. Number of participants who require a blood transfusion.

    Time frame: During Hospitalization (up to day 10)

    Need of blood transfusion

Secondary outcomes

  1. Estimeted blood lost after surgery.

    Time frame: During Hospitalization (up to day 3)

    Gross total blood loss was estimated utilizing the formula PBV × (Hctpre- Hctpost)/Hcta

  2. Number of participants with embolic complication.

    Time frame: During Hospitalization (up to day 10)

    Yes or No

Sponsors and collaborators

Lead sponsor

Piotr Biega

Other

Registry information

Official study title

Tranexamic Acid After Pathological Fracture Treated With Modular Arthroplasty: Retrospective Observational Study

Important dates

Study start
2018
Primary completion
2021
Study completion
2022
First posted
Feb 6, 2024
Registry last updated
Feb 6, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.